iSpecimen Increases Global Access to Hematopoietic Stem and Immune Cells – Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Devoted to supporting life science researchers who urgently pursue breakthroughs, iSpecimen today announced it has partnered with new providers of diseased and healthy hematologic tissue to offer one of the industrys largest, most integrated networks of donors and collection sites available while addressing proliferating demand for hematopoietic stem and immune cell products.

Now, researchers can readily access cells with highly specific characteristics through the iSpecimen Marketplace, an online platform that increases access to human biospecimens from specific patients and healthy donors that can provide them.

iSpecimen continues to expand its partner network around the world, enabling researchers to efficiently procure bone marrow aspirate, peripheral blood mononuclear cells (normal and mobilized), and whole bloodall with corresponding donor profile/clinical data from healthy and diseased donors. Researchers today increasingly use these types of tissue and cell products in their work to develop stem cell therapies, immunotherapies, vaccines, diagnostics, new treatments for infectious and autoimmune diseases, and in cell-based assays to advance drug discovery and preclinical development.

Precision orders are simple, centralized and efficient

Using the iSpecimen Marketplace, researchers gain centralized, single-source access to a vast and growing population of healthy donors and patients (e.g., solid and liquid tumors, autoimmune, and numerous other diseases) with hematopoietic and immune cell phenotypes that match their particular research study criteria. Moreover, the Specimen Marketplace enables researchers to conveniently select from a comprehensive list of donor attributes, specify exclusion criteria, request a quote, and order banked or prospectively collected specimens online. By centralizing specimen procurement through the Marketplace, researchers can save precious time and human resources via a single source of procurement, order management, contracting, compliance and data access.

Unparalleled online selection, customization, compliance and order management experiences

iSpecimen also announced today it has upgraded the iSpecimen Marketplace experience for hematopoietic and immune cell customers, enabling a uniquely convenient and customizable online product selection experience. Now, researchers can easily refine their specimen selections involving numerous parameters such as HLA type (low and high resolution), blood type, body mass index, ethnicity, race, age, and gender. The iSpecimen Marketplace also offers the industrys most comprehensive donor screening capability, permitting researchers to select the required scope of infectious disease testing such as CMV, hepatitis (B&C), HIV, West Nile Virus, syphilis, Chagas, and more.

The iSpecimen Marketplace incorporates a range of unique order management features into the hematopoietic and immune cell procurement experience, allowing researchers to centrally manage multiple quotes, orders, shipments, and invoices across a large partner network. Customers and partners can expect to see ongoing enhancements to the iSpecimen Marketplace, designed to continuously increase biospecimen access and improve key aspects of the biospecimen procurement journey.

As with any human biospecimen collection, iSpecimen ensures that cells are collected in accordance with U.S. Health and Human Services regulations as well as HIPAA guidelines. Biospecimens are also collected under iSpecimens IRB protocol with informed consent or under partners IRB/IEC protocols with informed consent, both of which have been reviewed and approved by iSpecimens compliance team.

Hematopoietic stem and immune cells are used in some of the newest and most exciting medical science occurring today, said Wayne Vaz, Vice President of Growth and Corporate Development. There is a clear market trend towards increasing supply chain efficiency while maintaining a high level of regulatory compliance, data integrity, product selection, speed, and scalability. With the iSpecimen Marketplace, everything is in one place online, streamlining the procurement of specimens much like popular websites do for flights, cars and hotels.

To learn more or to search iSpecimen hematopoietic stem and immune cell products, visit iSpecimen Marketplace. Login simply requires an email.

About iSpecimenHeadquartered in Lexington, MA, iSpecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. The privately held company has developed the iSpecimen Marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. Proprietary cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. Researchers easily and compliantly gain access to specimens to drive scientific discovery. Partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. Ultimately, healthcare advances for all. For more information about iSpecimen, please visit iSpecimen.com.

Follow this link:
iSpecimen Increases Global Access to Hematopoietic Stem and Immune Cells - Business Wire

Alternative medical treatments and compassionate use – Lexology

Patients who are beyond treatment under the standards of conventional medicine often seek help from alternative medical treatments; however, these methods pose not only medical risks for patients, but also legal risks for doctors.

Facts

A surgeon with qualifications in vascular, heart and thorax surgery treated seriously ill patients using an innovative method. The patients suffered from morbus Parkinson, multiple sclerosis, various forms of myatrophy and paralysis, traumatic spinal cord injuries, macular degenerations or psychiatric impairments such as autism. All of the patients were beyond treatment under the standards of conventional medicine. The surgeon treated them with stem cell therapy.

First-instance and appeal decisions

In April 2014 the Viennese Administrative Authority fined the surgeon under Section 49(1) of the Act on the Medical Profession for failing to observe patient welfare namely, for not evaluating the side effects and counterindications of using stem cell therapy to treat the abovementioned conditions.

In July 2015 the Viennese Administrative Tribunal(1) partly confirmed this decision. The tribunal ruled that potential health risks cannot be withheld from patients.

Supreme Administrative Court decision

On appeal, the Supreme Administrative Court(2) overruled the Viennese Administrative Tribunal's decision. The court held that the administrative tribunal had accused the surgeon of regularly using autologous stem cell therapy as a new treatment, even though clinical studies had yet to determine its benefits and risks.

According to the court, stem cells fall within the definition of medicinal products under Section 1 of the Medicinal Products Act.(3) The court could therefore revert to the doctrine and precedents on the off-label use of medicinal products. In its view, the tribunal had not shown that the treatment was clearly prohibited. Further, without a prohibition on the off-label use of medicinal products with marketing authorisation, such a prohibition cannot be based on the Medicinal Products Act. Therefore, an infringement of "compliance with existing rules according to sec 49 (1) Act on the Medical Profession" was not obvious.

The use of medicinal products or treatments that have not been clinically evaluated in terms of benefit-risk ratio for certain (new) indications is referred to as 'compassionate use'. The Declaration of Helsinki on ethical principles for medical research involving human subjects states as follows:

Unproven interventions in clinical practice

37. In the treatment of an individual patient, where proven interventions do not exist or other known interventions have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorised representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. This intervention should subsequently be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information must be recorded and, where appropriate, made publicly available.

According to legal literature, compassionate use is a deviation from medical standards in special treatment situations, either because the standard is unhelpful or no standard for the special treatment is available. Unlike clinical studies, it refers to individual cases and not to a clinical sample.

Under Section 49(1) of the Medical Profession Act physicians must observe the rules of medical science; however, these rules are only guidelines with respect to patient welfare insofar as it is possible to go beyond conventional medicine. Therefore, Section 49(1) does not prohibit compassionate use for patients who are beyond therapy under conventional medicine if they are comprehensively informed and the compassionate use makes objective sense.(4)

There is no legal definition of 'compassionate use' and no Supreme Court precedents in this regard. On 13 February 1956 the German Federal Court ruled(5) that a method of treatment is a clinical study and not a compassionate use if the method is applied not primarily in the interests of treating a patient, but in the interest of scientific research. A new method of treatment may be applied if the responsible medical evaluation and comparison of the expected benefits and risks of the new method with the standard treatment under consideration justify its application.(6)

New methods may be used only on patients who are fully informed that said methods imply unknown risks. Further, patients must be able to evaluate and consent to (or not) said risks.(7)

In the case at hand, all of the surgeon's patients were beyond treatment such that, according to the medical standard, no successful cure could be expected at the time of the treatment.

The Viennese Administrative Tribunal failed to establish that the applied treatment had posed a danger to the patients; rather, it stated only that health risks cannot be excluded without clinical studies. The tribunal reproached the applicant for integrating the method of treatment into regular clinical operations. Compassionate use that is legitimate in individual cases becomes illegitimate if it is adopted in regular clinical operations, as it becomes a regular treatment with an unverified method. This further implies that the person administering the treatment has applied it in multiple cases. It is unclear whether the application of a new therapy on a larger number of patients excludes the qualification of the treatment as compassionate use.

Insofar as the Viennese Administrative Tribunal questioned the surgeon's claim to have evaluated the risks of stem cell therapy in each case, the tribunal lacked evidence to evaluate the types of risk that would prohibit compassionate use. Further, the tribunal failed to establish the circumstances and specific patient information that would prohibit compassionate use. Therefore, the Supreme Administrative Court set aside the Viennese Administrative Tribunal's decision.

Comment

The Supreme Administrative Court's decision appears to favour a liberal approach to new therapies and compassionate use and enhances the possibilities for developing new therapies and alternative medicines in future. However, patient welfare remains paramount for qualifying a new method as compassionate use.

Endnotes

(1) VGW-001/047/26739/2014-28.

(2) 24 April 2019, RA 2015/11/0113.

(3) Kopecky, Stammzellenforschung in sterreich, 2008, 269.

(4) Resch and Wallner, Handbuch Medizinrecht (second edition), 2015, 222.

(5) III ZR 175/54.

(6) German Federal Court of Justice, 13 June 2006, VI ZR 323/04.

(7) German Federal Court of Justice, 13 June 2006, VI ZR 323/04 and Federal Court of Justice, 27 March 2007, VI ZR 55/05.

This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide.Register for a free subscription.

More here:
Alternative medical treatments and compassionate use - Lexology

Stem Cell Market to witness huge Growth during the forecast period 2019-2025: Advanced Cell Technology Inc, Cellartis AB, STEMCELL Technologies Inc …

CMR has added new market study to its database, titled Global and Regional Stem Cell Market Research Report Forecast 2025

To aid clients to develop their effective approaches for growth, our up coming general market trends study on the worldwide Stem Cell Market for its duration of 2019 into 2025. we offers Stem Cell market insights out of the statistics, accumulated by trusted industry informants such as manufacturers and channel partners, and decision makers, along with regulatory bodies Inside this Stem Cell market research Report. the circumstances driving the global markets evolution were recorded and also end builders and the firm accomplices had been indulgent. Crystal Market Research is trusted by Millions of people all across the globe for its unique research Reports.

Access FREE Research Report PDF @https://www.crystalmarketresearch.com/report-sample/HC043337

Continue

Inquiry detailed TOC of Research Report: https://www.crystalmarketresearch.com/send-an-enquiry/HC043337

Get Exclusive Discount on this report Now @https://www.crystalmarketresearch.com/check-discount/HC043337

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

sales@crystalmarketresearch.com

| Ph: +1-888-213-4282

More:
Stem Cell Market to witness huge Growth during the forecast period 2019-2025: Advanced Cell Technology Inc, Cellartis AB, STEMCELL Technologies Inc ...

It’s not ‘sorry’ but ‘thank you’ that seems to be the hardest word – Charity Today News

Britain is a nation famed for its politeness and good manners, with excuse me, sorry, please, and thank you being some of the nations most commonly used expressions. However, new research has shown that despite saying thank you to others 59 times a day, we struggle to find the words to express our gratitude when it matters most.

In the average day, actions which trigger the word thank you include holding a door open (69%), making a cup of tea (59%) or at the end of an email or phone call (48%).However, nearly half (46%) of Britons agree that in serious situations, like being helped through difficult times or being cared for during a physical illness, the words thank you are not enough to express gratitude. The research by blood cancer charity, Anthony Nolan, also shows that 50% of people have struggled to find adequate words to show their thanks when being helped through difficult times.

When looking back on lifes important moments, parents (37%) ranked highly in the list of people we wish wed given a more meaningful thank you. Grandparents (19%), friends (18%) and schoolteachers (15%) also made the list of those we wished wed given a more meaningful thank you to.

To mark Blood Cancer Awareness Month (September 2019), the power and the limitations of saying thank you are explored in a new series of films shot by world-renowned, portrait photographer, Rankin. His work sensitively captures the visible struggle as people who have received a life-saving stem cell transplant try to find the words to say thank you to their donors, known or anonymous.

Over 2,000 people a year in the UK need a stem cell transplant and Anthony Nolan is the leading charity that finds matching donors for people with blood cancer and gives them a second chance of life.

Rankin comments,Weve all experienced moments when weve been lost for words generally in times of extreme emotion. I feel privileged to have shared some of the recipients amazing journeys of hope and recovery, made possible by the selfless act of someone who has never met, nor may ever meet, them. Can you even begin to imagine what you would say if, and when, you met the person responsible for giving you a second chance at life?

When it comes to being cared for during a physical illness, 46% of Brits would struggle to thank those whove helped them. Other situations where people would struggle included being cared for during a mental health problem (39%), being provided with a safe space when it was needed the most (37%), the safe delivery of a newborn baby (35%) or being given financial help to achieve a goal (33%).

Whilst a face-to-face thank you ranked the highest (42%), one in ten (11%) believe the best way to share our heartfelt thanks is by letter.

Henny Braund, Chief Executive at Anthony Nolan added:

For someone with blood cancer, a stem cell transplant could be their last chance of survival and, every, day five people start their search for a matching stranger.

We want to give every family the opportunity to say thank you. Nobody should hear there is no matching donor for them which is why, at Anthony Nolan, were working hard to grow the stem cell register, carry out groundbreaking research and provide the best post-transplant care to give families a future. But without support, lives cant be saved.

To find out more about how to support Anthony Nolan, and view the Silent Thank You films and image gallery, please visit:www.anthonynolan.org/thankyouor search #SilentThankYou

See the original post here:
It's not 'sorry' but 'thank you' that seems to be the hardest word - Charity Today News

New Insight as to How Cells Maintain Their Identity – Nature World News

Sep 21, 2019 10:17 AM EDT

In the body's cells, some proteins are of vital importance as to which genes are active or turned off. Now, researchers from the University of Copenhagen and the Memorial Sloan Kettering Cancer Center have discovered which proteins are necessary in order to maintain the proper genetic regulation.

All of the more than 200 different cell types in our body contain the same DNA. Which of those genes that are expressed determine each cell type. Therefore, it is essential that the activity of the genes is controlled with great precision.

Thus, a stem cell may develop into anything from skin to a bone cell, depending on which parts of the genome that are expressed.

The researchers in Professor Kristian Helin's research group have for several years worked to understand the mechanisms that control whether a gene is active or inactive. This research is crucial to the understanding of how cells become specialized and maintain their identity, the normal embryonic development, and how various diseases may develop.

In a new study, researchers working at the Biotech Research & Innovation Center (BRIC) and the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen as well as the Memorial Sloan Kettering Cancer Center in New York have achieved crucial new results.

The results were recently published in the scientific journal Molecular Cell and provide insight into the ways in which epigenetic mechanisms control the activity of genes.

'In addition, the results may have an impact on the future treatment of certain cancers related to the studied protein complex, including lymphoma, leukemia and a special type of brain cancer that is often seen in children', says Kristian Helin, Professor at BRIC and Director of Research at the Memorial Sloan Kettering Cancer Center.

Turning On and Off

One of the key protein complexes that regulate whether genes are turned on or off is called PRC2. To ensure that the complex binds to the right places in the genome, a number of other proteins are associated with PRC2.

In the recently published article, the research group has studied the importance of six different proteins associated with PRC2, and the group has shown that all six proteins help direct PRC2 to the right places in the genome.

In 15 different combinations, the researchers removed the associated proteins from embryonic stem cells one by one. In this way, the researchers were able to study the contribution of each protein to the activity and binding of the PRC2 complex to specific areas. It was found that the ability to find the way to the right places in the genome remained intact until all six associated proteins were removed from the stem cells.

That finding surprised the researchers, says the study's lead author, Postdoc Jonas Hjfeldt:

'We assumed that each of the associated proteins was responsible for its own area to where the PRC2 complex should be guided. Instead, we saw that they all contributed to the places where the complex binds. As long as just one of the associated proteins were left, the ability remained intact', he says.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

Read more:
New Insight as to How Cells Maintain Their Identity - Nature World News

Abortion opponents hold memorials at fetal burial sites amid battle over how these remains should be treated – Walla Walla Union-Bulletin

CHICAGO Although 40 years have passed since her abortion, the woman at the cemetery described a sense of loss and regret that transcends time.

Someone will always be missing, is how Jennifer Shea explained the pain following her decision to terminate an unplanned pregnancy when she was 19 in 1979.

Yet the Chicago-area woman finds some comfort in praying at the site of a simple gray tombstone, which bears the epitaph HOLY INNOCENTS PREBORN CHILDREN OF GOD, at St. Mary Catholic Cemetery in southwest suburban Evergreen Park. It marks a grave where hundreds of human fetal remains were buried in 1987, salvaged by anti-abortion activists from a dumpster behind a now-defunct abortion clinic on Michigan Avenue.

Its the least I can do to honor my own lost child, to honor each of those here and to honor God for the mercy and forgiveness he has shown me, Shea told a crowd of roughly 80 gathered at the gravesite Sept. 14 for an annual event called the National Day of Remembrance for Aborted Children.

The prayer vigil was one of about 200 memorials held across the country, many at other burial sites of fetal remains. Locally, similar commemorations were held at the gravesites of aborted fetuses in west suburban Hillside and southwest suburban Romeoville.

These fetal tissues are often considered medical waste, typically disposed of in the same manner as the byproduct of other surgeries or health procedures.

Yet those against abortion have long held that fetal remains deserve a dignified burial akin to any human death. Now court rulings and federal policies are increasingly shifting in their favor, igniting emotional debate over what the remains of a fetus signify and how they should be handled in their final disposition.

The U.S. Supreme Court in May upheld an Indiana provision requiring burial or cremation following an abortion or miscarriage at a medical facility, legislation signed by the states former governor, Vice President Mike Pence. The law went into effect earlier this month.

The state of Indiana feels that fetal remains should be treated with the same dignity and respect that is usually given to deceased humans, said a spokeswoman for Indiana Attorney General Curtis Hill.

Planned Parenthood officials said in a statement that the restriction has nothing to do with medical care and was instead designed to shame and stigmatize women and families.

Texas earlier this month attempted to revive its burial of fetal remains law, which was blocked by a federal judge last year.

At best, enshrining the States view of pregnancy increases the grief, stigma, shame, and distress of women experiencing an abortion, whether induced or spontaneous, the Texas U.S. District judge found in 2018.

The matter is pending before a federal appeals court.

The Trump administration in June announced that it would be halting use of human fetal tissue in medical research by government scientists a priority of the presidents anti-abortion supporters but largely denounced by the scientific community.

This research is critical for the development of new treatments for a wide range of serious diseases, states a letter to the U.S. secretary of Health and Human Services that was signed by dozens of science and medical organizations, including the AIDS Foundation of Chicago and the Skokie-based International Society for Stem Cell Research.

At the memorial in Evergreen Park, participants lined up to approach the gravesite individually, each leaving a pink or blue carnation at the headstone.

Several priests spoke, and one lamented the news that more than 2,200 medically preserved fetal remains were discovered this month at the Will County home of a dead doctor who had performed abortions in Indiana. Authorities are still investigating that case.

this gruesome discovery exposes the reality of the abortion industry, which destroys innocent babies for profit on a similar scale every day, dismantling the lie that abortion is health care, said a statement released Monday by Marjorie Dannenfelser, president of the Susan B. Anthony List, a national organization that supports political candidates who oppose abortion.

The group of a half-dozen anti-abortion activists would head out after dark, making multiple trips over a two-month period in 1987 to retrieve boxes of hundreds of fetal remains discovered in the garbage behind a Chicago abortion clinic.

Monica Migliorino Miller, co-director of the National Day of Remembrance and a native of south suburban Chicago Heights, recounted these nights in her book Abandoned: The Untold Story of the Abortion Wars.

I was living an unusual life, digging through trash dumpsters on a Chicago loading dock and picking the bodies of human beings out of the trash, said Miller, who now lives in Michigan. I kept boxes of aborted children, draped with a rosary, in my closet. My mind became forever etched with the memory of hundreds of dismembered, broken bodies their blood, intestines and torn skin.

Before the burial, she and her colleagues displayed some of the fetuses outside the abortion clinic in May 1987, according to a Chicago Tribune story.

The demonstration was designed to highlight the abortion holocaust that is going on all over America today, Joseph Scheidler, then the executive director of the Chicago-based Pro-Life Action League, told the Tribune at the time.

A funeral service was held in 2001 at Resurrection Cemetery in Romeoville for aborted fetuses retrieved from a laboratory at a Wisconsin hospital.

Cardinal Joseph Bernardin in 1988 led a burial service for some 2,000 aborted fetuses laid to rest in two caskets at Queen of Heaven Catholic Cemetery in Hillside; the anti-abortion activists had taken those remains from the loading dock of a north suburban laboratory, according to a National Day of Remembrance website.

The cardinal in his homily spoke of how every life, at every stage of development from conception to natural death and in all its circumstances, is sacred and beloved by God, the Tribune reported.

Reproductive rights advocates were outraged.

Colleen K. Connell, now the executive director of the American Civil Liberties Union of Illinois, had called the burial a shameless publicity stunt.

Its one thing for the cardinal to say the Catholic Church is opposed to abortion, she told the Tribune at the time. But its quite another for him to participate in an action which demeans the personal privacy and integrity of women who may or may not be churchgoers.

She had questioned whether laws were violated in providing and transporting the fetuses as well as anyone who gave information on the location of the remains though she conceded there likely wouldnt be legal action without an individual to bring a complaint.

If these people respect human life, why cart this fetal tissue around the country and save it up for a media stunt? she had said.

To Miller, these burials were critical to illustrate that the unborn are human beings they are not trash, they are people, she said in a telephone interview.

Abortion opposition has been her lifes work, many times running afoul of the law: Miller estimated that shes been arrested more than 50 times at abortion protests across the country from 1978 to 2017, often for trespassing or disorderly conduct; she served seven months in jail after a demonstration in Wisconsin in 1989 and 32 more days in jail following a Michigan protest in 2017.

Social justice is not accomplished without radical acts of love, taking risks and making sacrifices on behalf of those who are oppressed, Miller said, adding that her acts were always nonviolent.

The National Abortion Federation in May released statistics citing a rise in incidents of trespassing, obstruction and vandalism directed at abortion providers last year. The organization attributed the increase to the growing anti-abortion rhetoric of politicians.

In 2018 the number of individuals attempting to intimidate patients and disrupt patient services continued to increase at an alarming rate, the report stated. We know those who oppose abortion feel emboldened to demonize abortion providers when they see elected officials spreading misleading propaganda and that was true in 2018.

(EDITORS: STORY CAN END HERE)

(EDITORS: BEGIN OPTIONAL TRIM)

Various tussles over the disposition of human fetal remains have played out in courtrooms and public demonstrations across the country.

A Catholic church in Boulder, Colo., in 2005 buried the ashes of hundreds of fetuses obtained from a mortuary contracted to cremate the remains by a local abortion clinic, which didnt know the ashes were being given to the church.

Police in 1992 arrested a clergyman in Buffalo, N.Y., for pushing a formaldehyde-soaked human fetus in the faces of abortion rights activists.

In 1985, the remains of more than 16,000 fetuses were buried in California and eulogized by President Ronald Reagan after a three-year battle over their disposition. Singer Pat Boone recorded a song called Sixteen Thousand Faces to honor the remains and protest abortion, according to the Los Angeles Times.

(END OPTIONAL TRIM)

At the local memorial service in Evergreen Park Sept. 14, participants recited a special prayer to end abortion.

I commit myself to be active in the pro-life movement, they vowed in unison, and never to stop defending life until all my brothers and sisters are protected.

Shea left a flower at the headstone along with the rest of the crowd. She serves as a Chicago-area regional coordinator for the national Silent No More Awareness Campaign, which speaks out to help others heal after abortions.

While the cemetery doesnt hold the remains of her terminated pregnancy, which occurred years before the burial, Shea said its important for her to pay her respects at the grave.

Because of the humanity of those lost lives, she said.

2019 Chicago Tribune

Visit the Chicago Tribune at http://www.chicagotribune.com

Distributed by Tribune Content Agency, LLC.

PHOTOS (for help with images, contact 312-222-4194): ABORTION-MEMORIALS

Go here to read the rest:
Abortion opponents hold memorials at fetal burial sites amid battle over how these remains should be treated - Walla Walla Union-Bulletin

Global Cell Isolation/Cell Separation Market Industry Analysis and Forecast (2019-2026) – ScoopJunction

Global Cell Isolation/Cell Separation Market was valued US$ XX Bn in 2018 and is expected to reach US$ 17.92 Bn by 2026, at a CAGR of around XX % during a forecast period.

The report covers all the trends and technologies playing a major role in the growth of the Cell Isolation/Cell Separation market during the forecast period. It highlights the drivers, restraints, and opportunities expected to influence the market growth during 2019-2026.

Request For FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/market-report/global-cell-isolation-cell-separation-market/34136/#requestforsample

Some of the market drivers for the cell isolation/cell separation market are increasing incidences & prevalence of chronic diseases with the aging population, technological advancement in cell isolation, growing demand for bio-pharmaceuticals, personalized medicine, and increasing stem cell research. Cell isolation or separation is a tool used to sort cells into a specific population from a heterogeneous group of cells without contamination. The use of cell isolation techniques helps to open the door of cell-based therapies and thereby improve the quality of treatment and clinical outcome.

However, the ethical issues regarding the isolation of embryonic stem cells and the high cost of cell separation instruments are expected to restrict the growth of this market during the forecast period.

Based on cell type, the human cell segment is expected to register a major revenue share in the cell isolation/cell separation market globally. Owing to increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the high frequency and growing incidence of diseases such as cancer.

Based on the product, the consumables segment is expected to witness the fastest growth during the forecast period. Because of the increasing investments by companies to develop advanced products and the rising government initiatives for improving cell-based research are driving the growth of this segment.

North America region is expected to grow at a XX % rate of CAGR during the forecast period owing to increasing government support for cancer and stem cell research, the expanding biotechnology and biopharmaceutical industries and the increasing prevalence of chronic and infectious diseases in which cell isolation is required for diagnosis and treatment. Which results in, increase in demand for cell isolation products.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Cell Isolation/Cell Separation Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Global Cell Isolation/Cell Separation Market.

Do Inquiry Before Purchasing Report Here: https://www.maximizemarketresearch.com/market-report/global-cell-isolation-cell-separation-market/34136/#inquiry

Scope of the Global Cell Isolation/Cell Separation Market

Global Cell Isolation/Cell Separation Market, By Product

Consumableso Reagents, Kits, Media, and Serao Beadso Disposables Instrumentso Centrifugeso Flow Cytometerso Magnetic-activated Cell Separator Systemso Filtration SystemsGlobal Cell Isolation/Cell Separation Market, By Cell Type

Human Cellso Differentiated Cellso Stem Cells Animal CellsGlobal Cell Isolation/Cell Separation Market, By Cell Source

Adipose Tissue Bone Marrow Cord Blood/Embryonic Stem CellsGlobal Cell Isolation/Cell Separation Market, By Technique

Centrifugation-based Cell Isolation Surface Marker-based Cell Isolation Filtration-based Cell IsolationGlobal Cell Isolation/Cell Separation Market, By Application

Biomolecule Isolation Cancer Research Stem Cell Research Tissue Regeneration & Regenerative Medicine In Vitro DiagnosticsGlobal Cell Isolation/Cell Separation Market, By End user

Research Laboratories and Institutes Hospitals and Diagnostic Laboratories Biotechnology and Biopharmaceutical Companies Other End UsersGlobal Cell Isolation/Cell Separation Market, By Region

North America Europe Asia Pacific Middle East & Africa South AmericaKay players operating in the Global Cell Isolation/Cell Separation Market

Thermo Fisher Scientific Beckman Coulter Becton, Dickinson and Company GE Healthcare Merck KgaA Miltenyi Biotech pluriSelect STEMCELL Technologies Inc. Terumo BCT Bio-Rad Laboratories Inc.

Browse Full Report with Facts and Figures of Cell Isolation/Cell Separation Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-isolation-cell-separation-market/34136/

MAJOR TOC OF THE REPORT

Chapter One: Cell Isolation/Cell Separation Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Isolation/Cell Separation Market Competition, by Players

Chapter Four: Global Cell Isolation/Cell Separation Market Size by Regions

Chapter Five: North America Cell Isolation/Cell Separation Revenue by Countries

Chapter Six: Europe Cell Isolation/Cell Separation Revenue by Countries

Chapter Seven: Asia-Pacific Cell Isolation/Cell Separation Revenue by Countries

Chapter Eight: South America Cell Isolation/Cell Separation Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Isolation/Cell Separation by Countries

Chapter Ten: Global Cell Isolation/Cell Separation Market Segment by Type

Chapter Eleven: Global Cell Isolation/Cell Separation Market Segment by Application

Chapter Twelve: Global Cell Isolation/Cell Separation Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +91 20 6630 3320/ +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more here:
Global Cell Isolation/Cell Separation Market Industry Analysis and Forecast (2019-2026) - ScoopJunction

Can old drugs put a leash on wandering cancer cells? – Newsroom

health & science

Can an immune system distracted by post-surgery healing allow previously dormant cancer cells to wake up and cause havoc? Scientists say the science isnt settled but old drugs may help.

For years theres been a question surrounding breast cancer surgery. Twelve to 18 months after surgery theres a high recurrence rate of cancer.

It was a dilemma put to the test in mice, the results suggestingthe bodys healing response to surgery could be the reason.

The hypothesis is while the body is busy healing a wound, the immune system is less able to keep cancer cells - which had already spread to other areas of the body - dormant.

Surprisingly, the study found giving the mice over-the-counter anti-inflammatory medicine before and after surgery could reduce the risk.

The study received a fair bit of attention. There was worry from some quarters it may lead to people rejecting important surgery. It also highlighted something as cheap as aspirin could improve patients outcomes.

According to University of Otago research fellow Dr Nicholas Fleming, surgery is almost always the best option.

His view is the science on surgery and cancer-spread isnot settled, and while there may be a risk, not having surgery creates a worse situation.

If you cut a cancer out early, hopefully you get all of the cancer and thats the end of it.

The later the surgery, the greater the chance the cancer has spread.

He describes the question of what causes cancer to spread as a million-dollar question. Heputs it down to a collection of mutations.

For the most part, cancer cells do one thing:life revolves around dividing.

But in the tumour some rebels emerge. Not content to simply divide, they leave home and roam the body. Eventually, these find new spots to colonise. In their new home they begin to divide once more, creating new tumours.

Thats why the most important thing in cancer treatment is treating people before they get to that point because after that it becomes very, very hard to save their lives.

Fleming has been looking at whether existing drugs thatare out of patent(and dirt cheap as a result)couldhelp fight cancer spread.

The idea of repurposing drugs is an area gaining traction. It was sparked by data showing diabetics taking metformin for their diabetes had a lower rate of cancer than those not taking it.

Since then, hundreds of drugs - not initially designed with cancer in mind - have been associated with effects on cancer.

Association isnt rock solid proof. The gold standard of proof comes from expensive clinical trials.

For old drugs with expired patents, this is an issue. Theres no financial incentive for drug companies to fund clinical trials of drugs they wont profit from.

As a publicly-funded researcher, Fleming is in a position to look at some of the off-patent drugs pharmaceutical companies arent interested in.

Rapamycin, used since the 1970s to stop transplants from being rejected, is one drug hes looked at. He describes it as anti-inflammatory and anti-migratory.

That drug can stop cells crawling. If you have cells that are migrating, you can stop them with that.

Fleming, who is also looking at pairing old drugs with the new immunotherapy drugs, is not the only scientist in New Zealand looking at repurposed drugs.

Gillies McIndoe Research Institute executive director Dr Swee Tans clinical trial is treating brain cancer with drugs thatcost $5 once every three months.

Its the worst brain cancer, its the most aggressive brain cancer. The median survival is that half the patients will die within 15 months after diagnosis. About half of them will recur within six months of treatment and once they have recurred, about half will die in six months.

He said 11 people currently in the trial wereliving longer than expected. The treatment uses blood pressure pills.

We say cancer is caused by stem cells that have misbehaved and caused cancer.

Tan uses the analogy of a beehive. A queen bee stem cell makes worker bees thatcreate the tumour, it also makes another queen bee thattravels elsewhere in the body and starts another hive.

He found the renin-angiotensin system, which regulates blood pressure and electrolyte balance, also controls the queen bee.

The implication is you might be able to design treatment to control cancer by controlling the cancer stem cells by using medications which control the renin-angiotensin system.

Delaying clinical proof is funding.

New Zealand spends $1 billion a year to treat cancer. That cost is escalating because of very expensive cancer drugs. If the government put aside 1 percent of that - $10 million a year to fund research like this - it will take this whole debate forward. It would allow the work to be done to prove it one way or the other.

Dr David Jennings, a Bay of Islands GP, thinks theres a case for not waiting for clinical trials.

As a GP hes seen the fireworks of cancer spread in patients. He also lost a close friend, and the process of trying to help turned him into an advocate for repurposed drugs.

His friends cancer had spread by the time it was diagnosed, but Jennings believes the repurposed drugs in conjunction with traditional cancer treatments extended his time, and improved its quality.

Lets say were losing 1000 patients a year, in 10 yearsthats 10,000 people. Thats a hell of a lot of people waiting for these studies to be done.

While clinical trials struggle to get funding, he thinks patients can take a lead, do research and talk to their GP. With repurposed drugs having been around for decades, side effects are well-known.

Were in a good position in New Zealand in terms of being able to repurpose drugs, but it will have to be a patient and doctor decision.

Read more:

Off-label and untapped - are old drugs new cancer treatments?

See more here:
Can old drugs put a leash on wandering cancer cells? - Newsroom

Sask. woman reflects on cancer journey before leading inaugural Multiple Myeloma March – News Talk 980 CJME

Southey's Mona Neher is leading the inaugural Multiple Myeloma March in Regina on Sept. 22, 2019. (Mona Neher/Submitted)

For the past decade, Mona Neher has wanted to hold a Multiple Myeloma March in Regina but she knew she couldnt do it alone.

This weekend, with help from others who have the same cancer, the Southey woman is making her dream a reality.

Neher was first diagnosed with myeloma (a form of blood cancer that targets plasma cells) in 2006 two years after fracturing her tailbone and ribs in a horseback-riding accident.

I had rib pain and fatigue, and I was wondering why this was going on, so I went to my doctor. Eventually, he sent me for X-rays and the X-rays came back with multiple myeloma, she remembered in an interview earlier this week.

At 39 years old with a young family at home, Neher said the diagnosis left her in a state of shock.

In the months that followed, she drove to Saskatoon for a stem cell transplant. With the help of the surgery and a phase two clinical medication trial, Neher launched into remission and back into the workforce as a registered nurse for 10 years.

In 2015, that familiar fatigue and pain picked up again, signalling that the cancer had returned. A year later, Neher underwent a second stem cell transplant that helped transition her back into remission, where she remains today.

While shes no longer working as a nurse, Neher now has a full-time job as an advocate, helping raise awareness about myeloma and holding support group meetings for those with the disease.

It might be a different type of myeloma (for each support group member) but we do understand what each other is going through and it just gives you strength to carry on, she explained.

With help from some of those support group members, Neher is leading the inaugural Multiple Myeloma March in Regina on Sunday. It starts at 10 a.m. at the RCMP Heritage Centre.

Neher said the event is a longtime coming; she has wanted to hold a march since it first originated 11 years ago.

Ive very happy about it and emotional about it, too, that it has finally come to this point. Im excited, she said.

Neher said there are two main goals of the five-kilometre walk: To raise $10,000 for research toward finding a cure to myeloma, and to help connect those newly diagnosed with the cancer.

I want (others with myeloma) to be positive and I know thats not necessarily what somebody wants to hear sometimes but there is hope, she encouraged. I know Im grateful for where Im at today, but it has been a journey.

Go here to see the original:
Sask. woman reflects on cancer journey before leading inaugural Multiple Myeloma March - News Talk 980 CJME

Circulating Tumor Cells and Cancer Stem Cells Market Estimated to Expand at a Robust CAGR over 2025 – Commerce Gazette

The tumor cells which have shed into lymphatic system and circulated over the body through blood circulation are called as circulating tumor cells. Circulating tumor cells may comprise seeds for metastasis. Stem cells are the type of cells that can differentiate into specialized cells and have the capacity of self-renewal. Cancer stem cells are the cancer cells that possess the characteristics of normal stem cells. Cancer stem cells are said to be responsible for relapse of cancers in patients. There is a growing interest in these two cell types due to their fundamental biological and clinical implications. Circulating tumor cells and cancer stem cells are an important element in order to understand cancer related mechanism and to find a cure from all type of cancers. These cells can be used for detecting of metastasis and the patients who are at a higher risk of cancer relapse.

The global circulating tumor cells and cancer stem cells market is anticipated to grow at a rapid rate owing to development in biotechnology and biomedical engineering. According to WHO, Cancer is the leading cause of mortality and morbidity globally impacting about 14 million people annually, leading to rapid increase in research activities worldwide. Circulating tumor cells and cancer stem cells are under research for various types of cancer such as breast cancer, lung cancer, colorectal cancer, skin cancer. Government and various government bodies are taking interest and initiative to boost funds and activities which is one of the major factor driving the growth of the global circulating tumor cells and cancer stem cells market. Increase in demand of oncology screening, diagnosis and treatment monitoring the patients disease progression is one of the factor likely to propel the growth of the market through 2024. Furthermore, application of the circulating tumor cell for the drug discovery, use of cells in development of tumor specific biomarkers for targeted therapies are driving the growth of the global market. However, the ethical issues involved in research and regulation to perform human trials are some of the major factor that are retraining the growth of the global market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/13306?source=atm

Based on technology type, the global circulating tumor cells and cancer stem cells market is divided into following Cell enrichment Detection CTC Analysis

Based on Application types, the global circulating tumor cells and cancer stem cells market is divided into following Biomarkers Tumorigenesis Stem cell research Others

The global circulating tumor cells and cancer stem cells market is segmented on the basis of technology type, application type and geographical region. On the basis of technology type the global market is divided into cell enrichment, Detection and CTC Analysis. Enrichment is further divided into positive selection, negative selection, Microchips and others. Detection is further divided into Immunocytochemicals technology, Molecular based technology, EPISPOT functional invitro assay. Cell Enrichment accounted for the largest market share globally owing to higher usage in oncology research and highly accurate technology. Microchip technology is expected to register high growth in the global market due to introduction of cluster chip technology which enables to capture the clusters of circulating tumor cells. On the basis of application type, the global market is divided into Biomarkers, tumorigenesis, stem cell research and others.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/13306?source=atm

Geographically the global circulating tumor cells and cancer stem cells market is divided into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is the dominating region in the global market attributing to the factors like developed economy, developed healthcare domain, strong funding for oncology research, rise in prevalence rate of cancer, favorable initiatives by government bodies. Asia Pacific region is expected to register high growth during the forecast period as a result of awareness, development of research and healthcare domains and prevalence of cancer.

Some of the major player operating in the global circulating tumor cells and cancer stem cells market are QIAGEN Hannover, AVIVA Biosciences, Epic Sciences, ApoCell, Cynvenio Biosystems, Fluxion Biosciences, Rarecells, Janssen Diagnostics, LLC, CellTraffix Inc., Silicon Biosystems, Advanced Cell Diagnostics, Inc. among others worldwide. To maintain a significant position in the global market key players are involved in collaboration with the cancer research universities and hospitals, for example in November 2015 Epic Sciences announced collaboration Abramson cancer Centre of University Pennsylvania. This collaboration is expected to explore the field of biomarkers which are identified by circulating tumor cells. The key participants are expanding the market by developing the facilities in different regions. For example, in September 2014 advanced cell diagnostic Inc. established a subsidiary in Europe to serve the European market.

The report covers exhaustive analysis on: Circulating Tumor Cells and Cancer Stem Cells Market Segments Circulating Tumor Cells and Cancer Stem Cells Market Dynamics Historical Actual Market Size, 2013 2015 Circulating Tumor Cells and Cancer Stem Cells Market Size & Forecast 2016 to 2024 Circulating Tumor Cells and Cancer Stem Cells Market Current Trends/Issues/Challenges Competition & Companies involved Circulating Tumor Cells and Cancer Stem Cells Market Drivers and Restraints

Regional analysis includes North America Latin America Europe Asia Pacific Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Request to view TOC at https://www.persistencemarketresearch.com/toc/13306?source=atm

Read the original here:
Circulating Tumor Cells and Cancer Stem Cells Market Estimated to Expand at a Robust CAGR over 2025 - Commerce Gazette